

OCT 24 2002

1023194

## 510(k) Summary

**Submitter**

LifeScan, Inc.  
1000 Gibraltar Drive  
Milpitas, CA 95035  
Contact: John E. Hughes  
Date Prepared: October 23, 2002

**Device Name**

SURESTEP®PRO Professional Blood Glucose Management System  
SURESTEP®FLEXX Professional Blood Glucose Management System  
Common name: Glucose test system

**Predicate Device**

SURESTEP®PRO Blood Glucose Monitoring System

**Device Description**

The SURESTEP®PRO and SURESTEP®FLEXX Systems consist of a test strip (SURESTEP®PRO Test Strips), a reflectance photometer, quality control solutions, and linearity solutions. Ancillary devices to aid in obtaining blood samples (e.g. lancing devices) and external data management computer software designed to facilitate storage and retrieval of results are also provided.

A sample is placed on a test strip and inserted into the reflectance photometer. Glucose in the sample reacts with oxygen in a glucose oxidase-catalyzed reaction yielding gluconic acid and hydrogen peroxide. A second enzyme, peroxidase, mediates transformation of indicator dyes into products with a blue color. The intensity of the resulting blue color is proportional to the concentration of glucose in the sample. The meter measures the amount of light reflected by this blue colored product and converts the reflectance data into a glucose concentration that is displayed on a liquid crystal display. The user adjusts the meter response for each lot of test strips by entering a calibration code specific to that lot of test strips.

**Intended Use**

The SURESTEP®PRO and the SURESTEP®FLEXX Professional Blood Glucose Management Systems are for *in vitro* diagnostic use for the quantitative measurement of glucose in venous, capillary, arterial, and neonatal whole blood samples. These systems can also be used by lay users at home.

**Comparison to Predicate Device**

The existing labeling for the SURESTEP®PRO Professional Blood Glucose Management System and the SURESTEP®FLEXX Professional Blood Glucose Management System has

been simplified to increase understanding and provide clear explanations of the performance capabilities and the performance limitations of the system.

### **Conclusion**

The modified SURESTEPPRO Professional Blood Glucose Management System and the SURESTEPFLEXX Professional Blood Glucose Management System is substantially equivalent to the predicate device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

OCT 24 2002

Mr. John E. Hughes  
Manager, Regulatory Submissions  
LifeScan, Inc.  
1000 Gibraltar Drive  
Milpitas, CA 95035-6312

Re: k023194  
Trade/Device Name: SureStep®Pro Professional Blood Glucose Management System  
SureStep®Flexx Professional Blood Glucose Management System  
Regulation Number: 21 CFR 862.1345  
Regulation Name: Glucose test system  
Regulatory Class: Class II  
Product Code: NBW; CGA  
Dated: September 24, 2002  
Received: September 25, 2002

Dear Mr. Hughes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style with a large, stylized 'S' and 'G'.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure


### ***Indications for Use Statement***

510(k) Number: \_\_\_\_\_

Device Name: SURESTEP®PRO Professional Blood Glucose Management System  
SURESTEP®FLEXX Professional Blood Glucose Management System

#### **Indications for Use:**

The SURESTEP®PRO and the SURESTEPFLEXX Professional Blood Glucose Management Systems are for *in vitro* diagnostic use for the quantitative measurement of glucose in venous, capillary, arterial, and neonatal whole blood samples. These systems can also be used by lay users at home.


  
(Division Sign-Off)  
Division of Clinical Laboratory  
510(k) Number K023194

---

Concurrence of CDRH, Office of Device Evaluation

Prescription Use \_\_\_\_\_  
(Per 21 CFR 801.109)

OR

Over-the-Counter Use  \_\_\_\_\_